Humanized Mouse Models for Precision Drug Discovery

Q: Are inducible or conditional hACE2 models available for tissue- or time-specific infection studies?

Yes, Cyagen offers inducible and conditional hACE2 mouse models: K18-hACE2-2A-CreERT2 Mice: Combine hACE2 expression with a tamoxifen-inducible Cre recombinase, allowing temporal control over gene expression. This model is ideal for studying the effects of SARS-CoV-2 infection at specific developmental stages or time points. ROSA26-LSL-hACE2 Mice: Enable tissue-specific expression of hACE2 when bred with mice expressing Cre recombinase under tissue-specific promoters, facilitating targeted studies of organ-specific infection and pathology.

Q: How precise is the integration of complete human genes? Can specific human isoforms or regulatory elements be accurately mimicked, and what are the limitations in terms of gene size or complexity?

Our proprietary TurboKnockout-Pro™ technology ensures unparalleled precision in complete human gene integration. This advanced approach allows for the seamless insertion of full-length human genes, accurately mimicking endogenous spatial and temporal expression patterns, thereby preserving natural regulation. This capability is critical for faithfully recapitulating human isoforms and their native regulatory elements, even for genes of significant size or complex genomic architecture, providing highly physiologically relevant models for your research.

Q: What are HUGO-GT's capabilities for high-throughput screening and generating custom models quickly?

HUGO-GT™ is designed for accelerated development and high-throughput use. Our ready-to-use models expedite research. For custom projects, our platform ensures rapid generation of new humanized lines, supporting efficient large-scale screening and efficacy studies with exceptional reproducibility.

Q: Given human gene integration, what are the potential immunological responses in the mouse model to the human gene products, and how does HUGO-GT™ account for or mitigate these?

The core principle of HUGO-GT™ is to integrate complete human genes under their native murine promoters, aiming to achieve human gene expression that mimics natural patterns as closely as possible within the mouse. While the study of human gene products in a murine host inherently involves consideration of immunological responses, our meticulous approach to natural regulation and full-length integration is designed to provide a physiologically relevant system. This strategy focuses on studying the human-specific biology and therapeutic interactions, thereby enabling researchers to focus on human-relevant outcomes for their studies.

Q: How do HUGO-GT™ models address potential immunological responses to human gene products in mice?

HUGO-GT™ integrates human genes under native murine promoters for natural expression. While mouse immunological responses to human products are inherent, our approach focuses on providing physiologically relevant systems to study human-specific biology and therapeutic interactions.

HUGO-GT^TM: Revolutionizing Humanized Mouse Models

Accelerating Drug Discovery with Precise Genome-Wide Humanization Experience accuracy and reliability in preclinical studies with HUGO-GT™ models, powered by our proprietary TurboKnockout-Pro technology.

Accelerating Development

Ready-to-use models speed up translational research workflows

Natural Regulation

Human gene expression mimics endogenous spatial and temporal patterns

Accurate Gene Expression

Full-length hACE2 knock-in under native murine promoter

Overview

Product

FAQs

Overview

Elevate Your Gene Therapy Research with HUGO-GT™

HUGO-GT™ revolutionizes gene therapy research by seamlessly integrating complete human genes into mouse genomes. Our advanced humanized mouse models deliver precision in disease modeling and enhanced translational relevance. Powered by proprietary TurboKnockout-Pro technology, HUGO-GT™ accelerates model development while ensuring exceptional reproducibility. Partner with the platform trusted by leading research institutions and pharmaceutical companies to advance drug development, therapeutic efficacy studies, and translational research.Explore how HUGO-GT™ is reshaping gene therapy research and discover its transformative impact on ongoing studies.

Explore Ready-to-Use Mouse Models

Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.

You Might Also Be Interested In

MouseAtlas Model Library

Search and access curated genetically engineered mouse strains

Turboknockout^® Gene Editing

Fast-track your research with our efficient gene targeting service.

Ophthalmic CRO Platform

Ocular disease models and IND-ready drug evaluation workflows

Gene Therapy CRO Platform

AI-guided AAV design and full-spectrum preclinical validation

Neuroscience CRO Platform

Validated CNS models with behavioral and molecular efficacy data

Antibody Discovery CRO Platform

Human antibody mice and AI tools for rapid therapeutic validation

Product

Model Selection Made Simple

Access Our Model Library >>

Base Strain

Catalog Number

Catalog Number	Name	Base Strain	Research Application
C001899	B6-huKIT	C57BL/6NCya	Mechanistic studies of KIT mutation–driven mast cell hyperplasia and systemic mastocytosis; Functional analysis of KIT mutations in GIST initiation, invasion, and metastasis; Investigation of hematopoietic stem cell self-renewal and differentiation, melanocyte biology, and melanoma pathogenesis; Preclinical evaluation of KIT-targeted TKIs and novel therapeutic strategies, including resistance mechanisms.
C001930	B6-huEPCAM	C57BL/6JCya	Screening, development and pre-clinical evaluation of EPCAM-targeted drugs; Research on tumor mechanisms and tumor immunotherapy.
C001647	B6-hFUS*R521C	C57BL/6JCya	Research on amyotrophic lateral sclerosis (ALS); Research on frontotemporal lobar degeneration/dementia (FTLD-FUS).
I001191	B6-hFUS	C57BL/6JCya	Research on amyotrophic lateral sclerosis (ALS); Research on frontotemporal lobar degeneration/dementia (FTLD-FUS).
I001209	B6-hTFRC/htau	C57BL/6Cya	Neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD); Research on iron metabolism disorders and tumor development; Preclinical studies of TFRC/MAPT-targeted therapeutic agents.
C001816	B6-hMADCAM1	C57BL/6NCya	MADCAM1-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis; Research on the primary sclerosing cholangitis; Research on type 1 diabetes; Research on certain cancers.
C001896	B6-huC3*R102G	C57BL/6JCya	Preclinical research on C3-targeted drugs; Research on Immune-related diseases caused by uncontrolled activation of the complement system (such as age-related macular degeneration (AMD)); Research in immunotherapy, oncology, etc.
C001410	B6-htau	C57BL/6JCya	Research on Frontotemporal dementia (FTD); Research on Alzheimer's disease (AD); Research on other neurodegenerative diseases.
C001836	B6-htau*P301S	C57BL/6JCya	Research on Frontotemporal dementia (FTD); Research on Alzheimer's disease (AD); Research on other neurodegenerative diseases.
C001835	B6-htau*P301L	C57BL/6JCya	Research on Frontotemporal dementia (FTD); Research on Alzheimer's disease (AD); Research on other neurodegenerative diseases.

Items: 1 to 10 of 159

...

FAQs

Frequently Asked Questions (FAQs)

Are inducible or conditional hACE2 models available for tissue- or time-specific infection studies?

How precise is the integration of complete human genes? Can specific human isoforms or regulatory elements be accurately mimicked, and what are the limitations in terms of gene size or complexity?

What are HUGO-GT's capabilities for high-throughput screening and generating custom models quickly?

Given human gene integration, what are the potential immunological responses in the mouse model to the human gene products, and how does HUGO-GT™ account for or mitigate these?

How do HUGO-GT™ models address potential immunological responses to human gene products in mice?

Citation Database

Molecular Therapy: Methods & Clinical Development, March, 2025

Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing

【Other】

Gut, February, 2025

E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression

【Other】

Cell Death & Disease, February, 2025

Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage

【Other】

Molecular Therapy, February, 2025

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

【Other】

Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.